Use of Factor VIIa or Factor VIIa equivalents for treating late complications of trauma
AssigneeNovo Nordisk HealthCare A/G
InventorsMads Axelsen, Elisabeth Erhardtsen, Brett E. Skolnick
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for preventing late complications in trauma patients.
Claims15
A method for preventing or attenuating one or more late complications of trauma, the method comprising administering to a patient in need of said preventing or attenuating an effective amount for said preventing or attenuating of Factor VIIa, wherein said patient does not suffer from a congenital or acquired bleeding disorder.
A method for reducing the risk of developing Acute Lung Injury (ALI) and/or Acute Respiratory Distress Syndrome (ARDS) in a trauma patient, the method comprising administering to said patient an effective amount for said reducing of Factor VIIa or a Factor VIIa equivalent.
A method for preventing or attenuating one or more late complications of trauma in a majority of trauma patients, said method comprising (i) administering to a group of trauma patients an effective amount for said preventing or attenuating of Factor VIIa;
- and (ii) observing a reduction in the frequency of occurrence of one or more late complications of trauma among said group of patients relative to the frequency of occurrence of said late complications that would have been expected in the same group of patients who had not received said Factor VIIa.
A kit of parts for preventing or attenuating one or more late complications of trauma, comprising
- A medicament comprising Factor VIIa or a Factor VIIa equivalent;
- and
- (ii) Instructions for Use describing that:
- a. A first dose containing at least about 150, preferably at least about 200 ug/kg Factor VIIa or a corresponding amount of a Factor VIIa equivalent, should be administered at the start of treatment;
- b. A second dose containing about 100 ug/kg Factor VIIa or a corresponding amount of a Factor VIIa equivalent should be administered one hour after the start of treatment.
Dependencies are inferred from the claim text.